Boston ScientificBSX
About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Employees: 53,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
201% more first-time investments, than exits
New positions opened: 226 | Existing positions closed: 75
31% more call options, than puts
Call options by funds: $1.07B | Put options by funds: $819M
28% more funds holding in top 10
Funds holding in top 10: 39 [Q4 2024] → 50 (+11) [Q1 2025]
20% more repeat investments, than reductions
Existing positions increased: 651 | Existing positions reduced: 541
10% more capital invested
Capital invested by funds: $120B [Q4 2024] → $132B (+$12.4B) [Q1 2025]
8% more funds holding
Funds holding: 1,484 [Q4 2024] → 1,601 (+117) [Q1 2025]
1.75% less ownership
Funds ownership: 90.61% [Q4 2024] → 88.86% (-1.75%) [Q1 2025]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Needham Mike Matson | 15%upside $115 | Buy Reiterated | 28 May 2025 |
Citigroup Joanne Wuensch | 25%upside $125 | Buy Maintained | 22 May 2025 |
Morgan Stanley Patrick Wood | 25%upside $125 | Overweight Maintained | 16 May 2025 |
Barclays Matt Miksic | 25%upside $125 | Overweight Maintained | 25 Apr 2025 |
Raymond James Jayson Bedford | 21%upside $121 | Strong Buy Maintained | 24 Apr 2025 |
Financial journalist opinion
Based on 22 articles about BSX published over the past 30 days
